LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

102.12 -4.64

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

99.83

Max

107.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+21.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.7B

14B

Ankstesnė atidarymo kaina

106.76

Ankstesnė uždarymo kaina

102.12

Naujienos nuotaikos

By Acuity

50%

50%

149 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-12 23:57; UTC

Karštos akcijos

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

2026-02-12 23:35; UTC

Uždarbis
Pagrindinės rinkos jėgos

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

2026-02-12 23:28; UTC

Uždarbis

Applied Materials Profit Rises on Soaring AI Demand -- Update

2026-02-12 21:47; UTC

Uždarbis

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

2026-02-13 00:00; UTC

Rinkos pokalbiai

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

2026-02-12 23:47; UTC

Rinkos pokalbiai

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

2026-02-12 23:38; UTC

Rinkos pokalbiai

Gold Steady; Could Undergo Technical Recovery -- Market Talk

2026-02-12 23:33; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

2026-02-12 23:09; UTC

Rinkos pokalbiai

South32's Hermosa Review Stokes Spending Fears -- Market Talk

2026-02-12 22:55; UTC

Uždarbis
Karštos akcijos

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

2026-02-12 22:46; UTC

Rinkos pokalbiai

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

2026-02-12 22:23; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

2026-02-12 22:00; UTC

Uždarbis

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Net $1.52B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

2026-02-12 22:00; UTC

Uždarbis

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

2026-02-12 21:57; UTC

Uždarbis

XP 4Q Rev BRL4.95B >XP

2026-02-12 21:52; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-12 21:47; UTC

Uždarbis

Morningstar 4Q Rev $641M >MORN

2026-02-12 21:39; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:38; UTC

Uždarbis

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

21.82% į viršų

12 mėnesių prognozė

Vidutinis 128.33 USD  21.82%

Aukščiausias 175 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

149 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat